Specialty Pharmacy

Top news of the day from across the healthcare landscape.

Top articles of the week from Specialty Pharmacy Times.

Transplanting organs from donors infected with hepatitis C found to be a viable option.

Rural areas have a higher rate of death for lung, colorectal, prostate, and cervical cancers.

Stem cells loaded with oncolytic herpes simplex virus significantly slowed tumor growth in mice.

Pitavastatin may serve as a potential treatment for drug-resistant ovarian cancer.

Attacking overgrown lamellipodia and filopodia could prevent cancer metastasis.

Top news of the day from across the health care landscape.

New generation of antiviral drugs cause significant reduction in the risk for the most common type of adult liver cancer in patients with HCV.

Large group employers report significant cost challenges associated with specialty drugs.

Integrating medical and pharmacy benefits may better inform employer management of specialty drugs.

One-third of patients with myelodysplastic syndrome progress to acute myeloid leukemia.

Investigational biosimilar to Herceptin is designed to treat HER2-positive early breast cancer.

Sexual risk behaviors are associated with increased HIV transmission and prevalence, yet women are largely understudied.

Hepatitis C virus is a major cause of liver-related morbidity and mortality.

Three healthcare veterans join NASP's governing board of directors.

Top news of the day from across the health care landscape.

Moses Zonana, CEO of Compliance Meds Technologies, discusses ways technology can be utilized to monitor adherence.

The combination tablet is approved to treat adults with hepatitis C genotypes 1-6 without cirrhosis or mild cirrhosis.

The concept of specialty at retail has the potential to unlock vast financial, contracted volume, and patient continuum of care opportunities attached to pharmaceutical products currently dispensed in specialty pharmacies.

The anticipated action date for drug that treats moderate-to-severe active ulcerative colitis is set for March 2018.

PrEP has been found to be effective in preventing HIV in high-risk populations.

Neratinib, a kinase inhibitor, is indicated to follow therapy with trastuzumab to prevent breast cancer recurrence.

Scientists identify several new variants that affect the risk of lung cancer development.

Romosozumab is being investigated to treat postmenopausal women with osteoporosis.

Top news of the day from across the health care landscape.

Trastuzumab is indicated as an adjuvant therapy for HER2-positive breast cancer, along with metastatic breast and gastric cancers.

New report provides insight into patient awareness and attitudes towards biosimilars.

Findings point towards an HIV vaccine that stimulates the production of these antibodies.

Promising immunotherapy may change the standard of care for kidney cancer.